XLV - Health Care Select Sector SPDR ETF

NYSEArca - Nasdaq Real Time Price. Currency in USD
94.52
+0.92 (+0.98%)
As of 2:50PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close93.60
Open93.87
Bid94.50 x 4000
Ask94.51 x 800
Day's Range93.81 - 94.53
52 Week Range78.74 - 94.53
Volume3,078,931
Avg. Volume6,325,415
Net Assets18.31B
NAV92.78
PE Ratio (TTM)N/A
Yield1.35%
YTD Return13.03%
Beta (3y)0.98
Expense Ratio (net)0.14%
Inception Date1998-12-16
Trade prices are not sourced from all markets
  • As trade tensions rise, there are other headwinds threatening economy too
    Yahoo Finance Video6 days ago

    As trade tensions rise, there are other headwinds threatening economy too

    Yahoo Finance's Seana Smith and Dion Rabouin talk to Ron Weiner of RDM Financial Group about the biggest threats to the U.S. economy and where investors can find deals.

  • Why states are more prepared for the next recession
    Yahoo Finance Video9 days ago

    Why states are more prepared for the next recession

    While some sectors, like housing, is still recovering from the financial crisis, many state governments have built up rainy day funds and are better prepared to weather the next recession. Yahoo Finance’s Seana Smith, Maylan Studart, Rick Newman and Dion Rabouin discuss.

  • All-Time highs: 6 stocks to buy
    CNBC Videos24 days ago

    All-Time highs: 6 stocks to buy

    The "Fast Money" traders give you 6 trades as the U.S. stock market hits all time highs.

  • MarketWatch2 days ago

    Health care ETF surges toward record in a broad sector rally

    The SPDR Health Care Select Sector ETF rose 0.7% toward a record high in afternoon trade Tuesday, with 55 of its 63 equity components gaining ground. Among the ETF's (XLV) members which are also Dow Jones Industrial Average components, Pfizer Inc.'s stock shot up 1.5%, putting it on track to close at the highest level since December 2001. Also, shares of Johnson & Johnson gained 0.6% toward an eight-month high, Merck & Co. Inc. tacked on 0.4% to sit just shy of its 17-year high reached last Thursday, and UnitedHealth Group Inc. slipped 0.1% and was 2.2% below its Sept. 6 record close of $269.65. The XLV's biggest gainer was Abiomed Inc.'s stock , which rallied 2.7%, while its biggest decliner was AbbVie Inc.'s stock , which shed 2.1% after California sued the company alleging the payment of illegal kickbacks. The XLV has rallied 11% over the past three months, while the Dow has tacked on 5.2%.

  • Investopedia4 days ago

    Top 3 Healthcare Stocks for 2018

    The healthcare industry is watching the Trump presidency closely. President Trump's promise to repeal and replace Obamacare hit repeated stumbling blocks in Congress. Despite the uncertainty surrounding these efforts to overhaul the nation's healthcare system, a number of healthcare stocks rose dramatically throughout 2017.

  • Why Is BSX Stock Trading at Its 14-Year High Today?
    Market Realist7 days ago

    Why Is BSX Stock Trading at Its 14-Year High Today?

    Currently, BSX stock is trading near its all-time high. Boston Scientific (BSX) stock has been on a bullish trend over the last year, driven by strong fundamentals, a robust acquisition strategy, and a diverse product pipeline. Why did BSX stock jump today?

  • JNJ Stock Up 7% in the Past Month: What Drove the Bulls?
    Market Realist7 days ago

    JNJ Stock Up 7% in the Past Month: What Drove the Bulls?

    On September 12, Johnson & Johnson (JNJ) stock closed at $139.36. That was a 0.61% rise from the previous day’s closing price of $138.51. Currently, JNJ stock is trading above its 50-day moving average of $133.29 and below its 200-day moving average of $127.99.

  • Eli Lilly Initiates New Trial for Taltz in Plaque Psoriasis
    Market Realist10 days ago

    Eli Lilly Initiates New Trial for Taltz in Plaque Psoriasis

    Eli Lilly (LLY) announced in a press release on September 10 that the company has initiated the IXORA-R head-to-head (or H2H) study evaluating the superiority of drugs Taltz (ixekizumab) and Tremfya (guselkumab) in patients with moderate-to-severe plaque psoriasis. The below chart shows key highlights for the IXORA-R H2H trial.

  • Investopedia10 days ago

    Top 3 Healthcare ETFs for 2018

    The solid performance of the healthcare market in the first eight months of 2018 has created investment opportunities. These ETFs are poised to take advantage.

  • Benzinga13 days ago

    Health Care Has Been On Fire. Will The Uptrend Continue?

    Health care has been the hottest sector of the US equities market over the last three months. According to Thomson Reuters Lipper Alpha, 94 percent of health care companies exceeded earnings expectations for the second quarter. A Goldman Sachs analysis concluded that hedge funds have more than 17 percent of their assets invested in health care, making it the largest weighting of any sector.

  • UnitedHealth Group Stock at 52-Week High, Up 22% Year-to-Date
    Market Realist14 days ago

    UnitedHealth Group Stock at 52-Week High, Up 22% Year-to-Date

    On September 5, UnitedHealth Group (UNH) ended the trading day at $267.64. The stock was marginally down from its previous day’s closing price. However, the stock registered its 52-week high of $270.17 last week on August 30. It was trading at its 52-week low of $186 on October 13, 2017.

  • MarketWatch15 days ago

    Anthem's stock hits record high after Morgan Stanley turns bullish, boosts price target

    MARKET PULSE Shares of Anthem Inc. (antm) rose 1.1% in afternoon trade Wednesday, but pared earlier gains of as much as 1.7% to an all-time intraday high of $268.28, after Morgan Stanley turned bullish on the the health insurer, saying that with great pharmacy-benefit-manager (PBM) disruption comes great opportunity.

  • Do Abiomed’s Valuations Look Attractive?
    Market Realist15 days ago

    Do Abiomed’s Valuations Look Attractive?

    Abiomed (ABMD) is a leading medical devices company. Its revenues rose 36% YoY to ~$180 million in fiscal Q1 2019 compared to $133 million in Q1 2018. The chart below compares revenues and EPS for Abiomed since the first quarter of 2018.

  • The stock market’s best investment strategy shows no sign of slowing
    MarketWatch15 days ago

    The stock market’s best investment strategy shows no sign of slowing

    Thus far this year, the best trade in the U.S. stock market is also the best trade of 2017, as well as the best of many others of the past several years.

  • ETF Trends16 days ago

    Healthcare ETFs Could be Tested in September

    The Health Care Select Sector SPDR (XLV) , the largest healthcare exchange traded fund by assets, gained about 4.3% in August to push its quarterly gain to 11.3%. Year-to-date, XLV is up more than 12%, underscoring the point that healthcare is one of the best-performing sectors after technology and consumer discretionary, but some market observers XLV's upside will be limited over the near-term. XLV allocates about two-thirds of its combined weight to pharmaceuticals and biotechnology stocks.

  • Illumina Stock Continues Its Bull Run
    Market Realist16 days ago

    Illumina Stock Continues Its Bull Run

    Illumina (ILMN) reached its 52-week high of $357.93 per share on August 31. On August 28, Illumina’s MiSeqDx sequencing system received approval in China. On August 16, ILMN stock fell ~2.1% in after-hours trading due to the news of the company’s plans to offer $650 million of convertible senior notes, which will be due by 2023.

  • Align Technology Continues to Rise, Stock Registers 52-Week High
    Market Realist20 days ago

    Align Technology Continues to Rise, Stock Registers 52-Week High

    Today, Align Technology (ALGN) reported a 52-week high of $392.69 per share. The stock momentum has seen strong growth momentum this year on strong quarterly performances and fundamentals. Align is currently trading higher than its 50-day moving average of $366.00 and its 200-day moving average of $308.74. The stock was trading at a 52-week low of $173.88 per share on September 1, 2017.

  • MarketWatch21 days ago

    Patterson Companies' stock takes a dive earnings miss, downbeat outlook

    Shares of Patterson Companies Inc. (pdco) plunged as much as 15% to a nine-year low in intraday trade, before bouncing to be down 5.8% in active afternoon trade, in the wake of the dental and animal health markets company's fiscal first-quarter results. Excluding non-recurring items, adjusted earnings per share came to 26 cents, below the FactSet consensus of 34 cents. Sales increased to $1.34 billion from $1.30 billion, above the FactSet consensus of $1.30 billion, as both dental supply and animal health sales topped expectations.

  • Investopedia22 days ago

    Active Traders Remain Bullish on Healthcare

    As sectors that are traditionally considered risky continue to be plagued with heightened volatility, the healthcare sector as a group has managed to continue its trend higher. In this article, we'll analyze several charts from across the healthcare sector and try to pinpoint how traders will look to position themselves over the weeks to come. Based on the number of trading opportunities that have started to pop up on common technical scans, it appears as though the healthcare sector is proportionately outperforming the other sectors.

  • MarketWatch27 days ago

    Popular health-care ETF finishes at an all-time high as stock market rallies

    A popular exchange-traded fund that tracks the health-care sector finished at its highest level in its history on Friday. The Health Care Select Sector SPDR ETF (XLV) advanced by 0.4% to reach 91.82, representing its highest level since the vehicle was created in 1998 to match the S&P 500 index's (SPX) health-care sector. The record for the health-care ETF underscores a rally on Wall Street in late August that has the small-capitalization Russell 2000 index (RUT) the Nasdaq Composite Index (COMP) and the S&P 500 putting records of their own.

  • Investopedia27 days ago

    Merck, Pfizer to Benefit From Pharma Surge: MS

    The technology sector may get all the attention as it continues to lead the bull run in the stock market. Despite a surge in health care stocks—the Health Care Select Sector SPDR ETF ( XLV) is 10.5% higher since the beginning of the year—Morgan Stanley thinks there’s still room for the sector to run. It’s particularly true when it comes to big pharma companies Merck & Co. Inc. ( MRK) and Pfizer Inc. ( PFE) according to Morgan Stanley analyst David Risinger. In a research note covered by Barron’s, the Wall Street analyst said as investors rotate out of growth stocks and into more defensive bets they are turning their sights to the health care market.

  • These 7 little-known health-care ETFs are up 20%-plus in 2018
    MarketWatch28 days ago

    These 7 little-known health-care ETFs are up 20%-plus in 2018

    While technology stocks tend to make the flashiest headlines, the health-care sector remains one of the most consistent outperformers. The top health-care exchange traded fund (ETF) by assets, the $18 billion Health Care Select SPDR ETF (XLV) has gained about 10% this year vs. 6% for the S&P 500 Index (SPX) And longer term, it’s up about 205% in 10 years vs. about 145% for the S&P 500. It’s no surprise, then, that investors closely follow these health-care funds and continue to invest plenty of funds in the leaders.

  • ETF Trends29 days ago

    7 Healthcare ETFs Among Best Performing Defensive Picks This Year

    The healthcare sector and related ETFs have been among the best performing defensive plays this year as strong earnings and potential Trump administration actions on drug pricing drew greater investment ...

  • 4 Sector ETFs Brimming With Inflows
    Zacks29 days ago

    4 Sector ETFs Brimming With Inflows

    If some sector ETFs attracted investors' attention past months, those were all defensive.

  • Recent Developments at Allergan
    Market Realistlast month

    Recent Developments at Allergan

    Allergan (AGN) is developing a variety of products through internal programs as well as in collaboration with other companies. A few of the products it currently has under development are Cenicriviroc, Atogepant, Bimatoprost SR, Ubrogepant, Abicipar, Rapastinel, and Sarecycline.